导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.70% | 2389/4773 |
| 近一周 | -2.95% | 3434/5462 |
| 近一月 | -7.61% | 3893/5421 |
| 近一季 | -13.63% | 4046/5209 |
| 近半年 | -2.20% | 1816/4920 |
| 近一年 | 1.52% | 2318/4366 |
| 近两年 | 61.49% | 1172/2954 |
| 近三年 | 33.22% | 926/2253 |
| 成立以来 | 75.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.83% 2513/4961 |
21.01% 1193/5312 |
- - |
- - |
| 2025 | 26.04% 1660/4813 |
-0.49% 2272/3635 |
-0.61% 2975/4076 |
30.17% 1195/4524 |
-2.10% 3091/4813 |
| 2024 | 14.90% 988/3463 |
0.31% 1000/2808 |
-3.29% 1337/3014 |
20.05% 771/3129 |
-1.35% 1663/3463 |
| 2023 | -14.98% 1629/2656 |
4.18% 1028/2280 |
-6.06% 1583/2385 |
-6.84% 1507/2515 |
-6.74% 1899/2655 |
| 2022 | -24.06% 1185/2207 |
-18.20% 1310/1919 |
9.02% 307/2016 |
-16.41% 1454/2113 |
1.89% 1098/2208 |
| 2021 | 2.02% 643/1822 |
-4.07% 846/1255 |
11.14% 395/1330 |
-7.19% 1030/1466 |
3.09% 474/1822 |
| 2020 | 49.75% 176/1250 |
-5.48% 423/1028 |
21.67% 228/1067 |
10.35% 561/1164 |
18.01% 107/1184 |
| 2019 | 56.14% 67/1092 |
37.63% 71/739 |
-2.87% 361/788 |
4.78% 182/850 |
11.47% 58/918 |
| 2018 | -31.99% 512/834 |
- - |
-10.77% 329/631 |
-9.03% 506/660 |
-13.75% 553/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商深证100指数C VS. 长安沪深300非周期A(740101) |